- Home
- ASO vs PBLS Comparison
ASO vs PBLS Comparison
Compare ASO & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASO | PBLS |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ASO | PBLS |
|---|---|---|
| Price | $46.22 | $30.34 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $58.08 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 544.5K |
| Earning Date | 06-09-2026 | N/A |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $6,053,414,000.00 | N/A |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $56.85 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $41.29 | $25.56 |
| 52 Week High | $62.45 | $33.65 |
Technical Indicators
Market Signals| Indicator | ASO | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 62.34 |
| Support Level | $41.29 | $26.68 |
| Resistance Level | $60.27 | $30.19 |
| Average True Range (ATR) | 1.88 | 2.45 |
| MACD | -0.23 | 0.29 |
| Stochastic Oscillator | 25.83 | 57.11 |
Price Performance
Historical ComparisonAbout ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About PBLS Parabilis Medicines Inc. Common Stock
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.